BRPI0717834B8 - purificação de polissacarídeos tipo 3 de streptococcus pneumoniae - Google Patents
purificação de polissacarídeos tipo 3 de streptococcus pneumoniaeInfo
- Publication number
- BRPI0717834B8 BRPI0717834B8 BRPI0717834A BRPI0717834A BRPI0717834B8 BR PI0717834 B8 BRPI0717834 B8 BR PI0717834B8 BR PI0717834 A BRPI0717834 A BR PI0717834A BR PI0717834 A BRPI0717834 A BR PI0717834A BR PI0717834 B8 BRPI0717834 B8 BR PI0717834B8
- Authority
- BR
- Brazil
- Prior art keywords
- lysate
- methods
- precipitation
- cause
- aggregation
- Prior art date
Links
- 150000004676 glycans Chemical class 0.000 title abstract 3
- 229920001282 polysaccharide Polymers 0.000 title abstract 3
- 239000005017 polysaccharide Substances 0.000 title abstract 3
- 241000193998 Streptococcus pneumoniae Species 0.000 title abstract 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 title abstract 2
- 238000000746 purification Methods 0.000 title 1
- 239000006166 lysate Substances 0.000 abstract 8
- 238000000034 method Methods 0.000 abstract 6
- 238000001556 precipitation Methods 0.000 abstract 3
- 230000006920 protein precipitation Effects 0.000 abstract 3
- 230000002776 aggregation Effects 0.000 abstract 2
- 238000004220 aggregation Methods 0.000 abstract 2
- 238000010438 heat treatment Methods 0.000 abstract 2
- 238000010979 pH adjustment Methods 0.000 abstract 2
- 230000004845 protein aggregation Effects 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000001413 cellular effect Effects 0.000 abstract 1
- 239000012535 impurity Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
métodos para a redução ou remoção de impurezas protéicas de um lisado celular de streptococcus pneumoniae compreendendo polissacarídeos sorotlpo 3 a presente invenção refere-se a métodos aperfeiçoados para a redução ou remoção de impurezas protéicas de um complexo lisato ou centrado celular de streptococcus pneumoniae que compreende polissacarídeos sorotipo 3, envolvendo etapas que referem-se a aquecimento pós-lise ou ajuste de ph. em certos métodos, o lisado é aquecido por um tempo e a uma temperatura suficiente para desnaturar proteínas presentes no lisado e provocar sua agregação e precipitação. em uma modalidade, o lisado é aquecido a pelo menos 60°c por pelo menos 30 minutos para causar agregação e precipitação de proteínas, mais particularmente cerca de 60°c a cerca de 70°c por cerca de 30 a cerca de 50 minutos, e ainda mais particularmente a cerca de 65°c por cerca de 40 minutos. em outros métodos, o ph do lisado ou centrado é elevado para pelo menos 8,0 para aperfeiçoar capacidade de filtração, mais particularmente cerca de 8,0 a 8,4, e ainda mais particularmente cerca de 8,2. em métodos adicionais, etapas de aquecimento e ajuste de ph são combinadas para provocar a agregação e precipitação de proteínas, bem como para aperfeiçoar capacidade de filtração dos lisados ou centrados. em outros métodos, o ph do lisado ou centrado é baixado para cerca de 3,0 a cerca de 5,0 para causar agregação e precipitação de proteínas. tais métodos permitem a produção de lisados ou centrados que contêm polissacarídeos sorotipo 3 substancialmente purificados.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR122019021950A BR122019021950B8 (pt) | 2006-10-10 | 2007-10-09 | métodos para a redução ou remoção de impurezas protéicas de um lisado ou centrado celular de streptococcus pneumoniae compreendendo polissacarídeos sorotipo 3 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85066506P | 2006-10-10 | 2006-10-10 | |
| PCT/US2007/080768 WO2008045852A2 (en) | 2006-10-10 | 2007-10-09 | Purification of streptococcus pneumoniae type 3 polysaccharides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0717834A2 BRPI0717834A2 (pt) | 2014-06-10 |
| BRPI0717834B1 BRPI0717834B1 (pt) | 2020-05-19 |
| BRPI0717834B8 true BRPI0717834B8 (pt) | 2021-05-25 |
Family
ID=39156240
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0717834A BRPI0717834B8 (pt) | 2006-10-10 | 2007-10-09 | purificação de polissacarídeos tipo 3 de streptococcus pneumoniae |
| BR122019021950A BR122019021950B8 (pt) | 2006-10-10 | 2007-10-09 | métodos para a redução ou remoção de impurezas protéicas de um lisado ou centrado celular de streptococcus pneumoniae compreendendo polissacarídeos sorotipo 3 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR122019021950A BR122019021950B8 (pt) | 2006-10-10 | 2007-10-09 | métodos para a redução ou remoção de impurezas protéicas de um lisado ou centrado celular de streptococcus pneumoniae compreendendo polissacarídeos sorotipo 3 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7659090B2 (pt) |
| JP (1) | JP5260531B2 (pt) |
| KR (1) | KR101467002B1 (pt) |
| CN (2) | CN102648979B (pt) |
| AT (1) | ATE473289T1 (pt) |
| AU (1) | AU2007307800C1 (pt) |
| BR (2) | BRPI0717834B8 (pt) |
| CA (1) | CA2665169C (pt) |
| CL (1) | CL2007002909A1 (pt) |
| DE (1) | DE602007007642D1 (pt) |
| DK (1) | DK2074221T3 (pt) |
| ES (1) | ES2346929T3 (pt) |
| IL (2) | IL197782A (pt) |
| MX (1) | MX2009003730A (pt) |
| PT (1) | PT2074221E (pt) |
| RU (1) | RU2460539C2 (pt) |
| WO (1) | WO2008045852A2 (pt) |
| ZA (1) | ZA200902502B (pt) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
| BRPI0922981A8 (pt) | 2008-12-18 | 2019-11-26 | Wyeth Llc | método para o controle do peso molecular polissacarídeo para o sorotipo 19a de streptococcus pneumoniae |
| ES2749952T3 (es) | 2008-12-18 | 2020-03-24 | Wyeth Llc | Procedimiento de control del peso molecular de polisacáridos de Streptococcus pneumoniae usando carbono |
| EP2411048B1 (en) | 2009-03-24 | 2020-05-06 | GlaxoSmithKline Biologicals SA | Adjuvanting meningococcal factor h binding protein |
| EP3017826A1 (en) | 2009-03-24 | 2016-05-11 | Novartis AG | Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates |
| US20120052088A1 (en) | 2009-04-30 | 2012-03-01 | Coley Pharmaceutical Group, Inc. | Pneumococcal vaccine and uses thereof |
| AU2011268507B2 (en) | 2010-06-25 | 2014-08-14 | Novartis Ag | Combinations of meningococcal factor H binding proteins |
| CN102094053B (zh) * | 2010-11-26 | 2013-01-16 | 兰州生物制品研究所有限责任公司 | 肺炎链球菌c多糖的纯化方法 |
| WO2012117377A1 (en) | 2011-03-02 | 2012-09-07 | Novartis Ag | Combination vaccines with lower doses of antigen and/or adjuvant |
| JP2015505309A (ja) | 2011-12-29 | 2015-02-19 | ノバルティス アーゲー | 髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ |
| JP2015510872A (ja) | 2012-03-07 | 2015-04-13 | ノバルティス アーゲー | Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤 |
| EP2822584A1 (en) | 2012-03-08 | 2015-01-14 | Novartis AG | Combination vaccines with tlr4 agonists |
| JP6324961B2 (ja) | 2012-09-06 | 2018-05-16 | ノバルティス アーゲー | 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン |
| RU2606022C2 (ru) | 2012-09-07 | 2017-01-10 | Ск Кемикалс Ко., Лтд. | Способ получения капсульного полисахарида с пневмококковым серотипом |
| US20150320852A1 (en) | 2012-12-18 | 2015-11-12 | Glaxosmithkline Biologicals Sa | Conjugates for protecting against diphtheria and/or tetanus |
| PL3096786T3 (pl) | 2014-01-21 | 2021-11-08 | Pfizer Inc. | Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty |
| BR112016015835B1 (pt) | 2014-01-21 | 2023-12-26 | Pfizer Inc | Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae |
| CN110859957B (zh) | 2014-01-21 | 2024-04-12 | 辉瑞公司 | 包含缀合荚膜糖抗原的免疫原性组合物及其用途 |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| HUE062499T2 (hu) | 2015-01-15 | 2023-11-28 | Pfizer | Pneumococcus-vakcinákban történõ alkalmazásra szolgáló immunogén készítmények |
| WO2016174683A1 (en) | 2015-04-28 | 2016-11-03 | Biological E Limited | Method for separation of protein and other impurities from microbial capsular polysaccharides |
| MY182282A (en) | 2015-05-04 | 2021-01-18 | Pfizer | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
| KR102225282B1 (ko) | 2015-07-21 | 2021-03-10 | 화이자 인코포레이티드 | 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도 |
| JP6884145B2 (ja) | 2015-11-20 | 2021-06-09 | ファイザー・インク | 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物 |
| CA3031797A1 (en) | 2016-08-05 | 2018-02-08 | Sanofi Pasteur, Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| CA3031799A1 (en) | 2016-08-05 | 2018-02-08 | Sanofi Pasteur, Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| CN110366428B (zh) | 2016-12-30 | 2024-05-17 | Vaxcyte公司 | 具有非天然氨基酸的多肽-抗原缀合物 |
| BR112019014833A2 (pt) | 2017-01-20 | 2020-04-14 | Pfizer | composições imunogênicas para uso em vacinas pneumococais |
| EP4656208A3 (en) | 2017-01-31 | 2026-03-04 | Merck Sharp & Dohme LLC | Methods for making polysaccharide-protein conjugates |
| JP7680185B2 (ja) | 2017-02-24 | 2025-05-20 | メルク・シャープ・アンド・ドーム・エルエルシー | 肺炎連鎖球菌多糖－タンパク質コンジュゲートの免疫原性の増強 |
| JP7111799B2 (ja) | 2017-07-05 | 2022-08-02 | インベントプライズ リミテッド ライアビリティ カンパニー | 溶菌酵素、接線流濾過、及びマルチモードクロマトグラフィを用いたワクチン生産のための多糖精製 |
| US10702596B2 (en) | 2017-07-05 | 2020-07-07 | Inventprise, Llc | Polysaccharide purification for vaccine production using lytic enzymes, tangential flow filtration, and multimode chromatography |
| MX394767B (es) | 2017-09-07 | 2025-03-24 | Merck Sharp & Dohme Llc | Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora. |
| MX394768B (es) | 2017-09-07 | 2025-03-21 | Merck Sharp & Dohme Llc | Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina. |
| ES3058336T3 (es) | 2017-12-06 | 2026-03-10 | Merck Sharp & Dohme Llc | Composiciones que comprenden conjugados polisacárido-proteína de Streptococcus pneumoniae y métodos de uso de los mismos |
| BR112020014978A2 (pt) | 2018-02-05 | 2020-12-22 | Sanofi Pasteur, Inc. | Composição de conjugado polissacarídeo-proteína pneumocócico multivalente |
| EP3749357A4 (en) | 2018-02-05 | 2022-04-20 | Sanofi Pasteur, Inc. | POLYVALENT PNEUMOCOCCAL POLYSACCHARIDE PROTEIN CONJUGATE COMPOSITION |
| US12144855B2 (en) | 2018-04-30 | 2024-11-19 | Merck Sharp & Dohme Llc | Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres |
| EP3788143B1 (en) | 2018-04-30 | 2023-06-28 | Merck Sharp & Dohme LLC | Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide |
| EP3787673A4 (en) | 2018-04-30 | 2022-04-27 | Merck Sharp & Dohme Corp. | Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates |
| WO2020010016A1 (en) | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Self-adjuvanted immunogenic conjugates |
| DK3817775T3 (da) | 2018-07-04 | 2024-09-16 | Vaxcyte Inc | Forbedringer i immunogene konjugater |
| CA3120922A1 (en) | 2018-12-12 | 2020-06-18 | Pfizer Inc. | Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof |
| CR20210333A (es) | 2018-12-19 | 2021-08-18 | Merck Sharp & Dohme | Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso |
| WO2020208502A1 (en) | 2019-04-10 | 2020-10-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| PH12022550110A1 (en) | 2019-07-31 | 2022-12-12 | Sk Bioscience Co Ltd | Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same |
| US12473379B2 (en) * | 2019-09-06 | 2025-11-18 | Serum Institute Of India Private Limited | Method for obtaining purified bacterial polysaccharides |
| CN114555618A (zh) * | 2019-10-01 | 2022-05-27 | 格礼卡姆股份公司 | 发酵液中中性寡糖的分离 |
| CN119371566A (zh) * | 2020-02-21 | 2025-01-28 | 辉瑞公司 | 糖类的纯化 |
| US12497640B2 (en) * | 2020-05-14 | 2025-12-16 | Serum Institute Of India Private Limited | Methods for simultaneous fragmentation and purification of bacterial polysaccharides |
| KR20230056727A (ko) | 2020-08-26 | 2023-04-27 | 화이자 인코포레이티드 | B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도 |
| WO2022084852A1 (en) * | 2020-10-22 | 2022-04-28 | Pfizer Inc. | Methods for purifying bacterial polysaccharides |
| CA3200602A1 (en) | 2020-11-04 | 2022-05-12 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| JP7804673B2 (ja) | 2020-11-10 | 2026-01-22 | ファイザー・インク | コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用 |
| JP2024517780A (ja) | 2021-05-03 | 2024-04-23 | ファイザー・インク | 細菌およびベータコロナウイルス感染症に対するワクチン接種 |
| WO2022234416A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| JP2024521847A (ja) | 2021-05-28 | 2024-06-04 | ファイザー・インク | コンジュゲート化莢膜糖抗原を含む免疫原性組成物およびその使用 |
| MX2023013434A (es) | 2021-05-28 | 2023-12-12 | Pfizer | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos. |
| CA3247998A1 (en) | 2022-01-13 | 2023-07-20 | Pfizer Inc. | Immunogenic compositions based on conjugated capsular saccharidic antigens and their uses |
| WO2024084397A1 (en) | 2022-10-19 | 2024-04-25 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| WO2024110827A1 (en) | 2022-11-21 | 2024-05-30 | Pfizer Inc. | Methods for preparing conjugated capsular saccharide antigens and uses thereof |
| EP4622665A2 (en) | 2022-11-22 | 2025-10-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| AU2023403045A1 (en) | 2022-12-01 | 2025-06-12 | Pfizer Inc. | Pneumococcal conjugate vaccine formulations |
| WO2024166008A1 (en) | 2023-02-10 | 2024-08-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| PE20252774A1 (es) | 2023-03-30 | 2025-12-22 | Pfizer | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos |
| AU2024255922A1 (en) | 2023-04-14 | 2025-10-30 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024224266A1 (en) | 2023-04-24 | 2024-10-31 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| KR20260015203A (ko) | 2023-05-19 | 2026-02-02 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 호흡기 세포융합 바이러스 및 스트렙토코쿠스 뉴모니아에 감염에 대한 면역 반응을 유발하는 방법 |
| TW202527906A (zh) | 2023-09-14 | 2025-07-16 | 美商輝瑞股份有限公司 | 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途 |
| WO2025133971A1 (en) | 2023-12-23 | 2025-06-26 | Pfizer Inc. | Improved methods for producing bacterial capsular saccharide glycoconjugates |
| WO2025186705A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2025219904A1 (en) | 2024-04-19 | 2025-10-23 | Pfizer Inc. | Improved methods for producing glycoconjugates by reductive amination in aprotic solvent |
| WO2025219908A2 (en) | 2024-04-19 | 2025-10-23 | Pfizer Inc. | Media and fermentation methods for polysaccharide production in bacterial cell culture |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4413057A (en) * | 1980-04-14 | 1983-11-01 | Merck & Co., Inc. | Group B streptococcal capsular polysaccharides |
| CA2059692C (en) * | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
| ATE459373T1 (de) * | 1999-03-19 | 2010-03-15 | Glaxosmithkline Biolog Sa | Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae |
| AU2001245795B2 (en) * | 2000-03-16 | 2005-07-28 | The Children's Hospital Of Philadelphia | Modulating production of pneumococcal capsular polysaccharide |
| GB0115176D0 (en) * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| US20050220777A1 (en) * | 2003-11-21 | 2005-10-06 | Stefan Roos | Selection of lactic acid bacteria enhancing the immune response against Streptococcus pneumoniae |
| CN101155833B (zh) * | 2005-04-08 | 2011-04-20 | 惠氏公司 | 通过pH操作将污染物与肺炎链球菌多糖分离 |
| EP1976857A4 (en) * | 2006-01-13 | 2011-08-03 | Baxter Int | PROCESS FOR CLEANING POLYSACCHARIDES |
-
2007
- 2007-10-09 DK DK07843999.9T patent/DK2074221T3/da active
- 2007-10-09 AU AU2007307800A patent/AU2007307800C1/en active Active
- 2007-10-09 JP JP2009532526A patent/JP5260531B2/ja active Active
- 2007-10-09 AT AT07843999T patent/ATE473289T1/de active
- 2007-10-09 CL CL200702909A patent/CL2007002909A1/es unknown
- 2007-10-09 PT PT07843999T patent/PT2074221E/pt unknown
- 2007-10-09 RU RU2009112453/10A patent/RU2460539C2/ru active
- 2007-10-09 KR KR1020097009585A patent/KR101467002B1/ko active Active
- 2007-10-09 BR BRPI0717834A patent/BRPI0717834B8/pt active IP Right Grant
- 2007-10-09 DE DE602007007642T patent/DE602007007642D1/de active Active
- 2007-10-09 BR BR122019021950A patent/BR122019021950B8/pt active IP Right Grant
- 2007-10-09 CN CN201210083999.1A patent/CN102648979B/zh active Active
- 2007-10-09 WO PCT/US2007/080768 patent/WO2008045852A2/en not_active Ceased
- 2007-10-09 ES ES07843999T patent/ES2346929T3/es active Active
- 2007-10-09 US US11/869,206 patent/US7659090B2/en active Active
- 2007-10-09 MX MX2009003730A patent/MX2009003730A/es active IP Right Grant
- 2007-10-09 CA CA2665169A patent/CA2665169C/en active Active
- 2007-10-09 CN CN2007800378009A patent/CN101522906B/zh active Active
-
2009
- 2009-03-24 IL IL197782A patent/IL197782A/en active IP Right Grant
- 2009-04-09 ZA ZA200902502A patent/ZA200902502B/xx unknown
-
2014
- 2014-07-31 IL IL233893A patent/IL233893A/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0717834B8 (pt) | purificação de polissacarídeos tipo 3 de streptococcus pneumoniae | |
| UA99278C2 (ru) | Способ получения существенно очищенных капсульных полисахаридов из лизата клеток streptococcus pneumoniae | |
| MX2019005911A (es) | Anticuerpos anti_cd137 novedosos y usos de estos. | |
| EA201070987A1 (ru) | Очищенные гибридные белки иммуноглобулина и способы их очищения | |
| MX2007001638A (es) | Proteinas de fusion del dominio de unión. | |
| ATE537188T1 (de) | Serumalbuminbindende proteine | |
| WO2007095506A8 (en) | Oligosaccharide modification and labeling of proteins | |
| MX348154B (es) | Anticuerpos de enlace a il-1-beta y fragmentos de los mismos. | |
| WO2008074840A3 (en) | Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders | |
| WO2010017103A3 (en) | Fully human anti-human nkg2d monoclonal antibodies | |
| BRPI0923786C1 (pt) | compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos | |
| ATE543810T1 (de) | Hemmer des 5-lipoxygenase aktivierenden proteins (flap) | |
| MX2012005864A (es) | Proteinas de enlace al antígeno anti-orai 1 y usos de las mismas. | |
| WO2006087637A3 (en) | Anti her2/neu antibody | |
| WO2010142551A8 (en) | Amino acid sequences directed against receptors to cytokines belonging to the il-17 family | |
| TN2009000442A1 (en) | Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90 | |
| WO2007052168A3 (en) | Fed batch culture methods for streptococci | |
| WO2009043922A3 (en) | Extracellular targets for alzheimer's disease | |
| WO2008033556A3 (en) | High pressure treatment of proteins for reduced immunogenicity | |
| IL218442A0 (en) | Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma | |
| CN106244570A (zh) | 一种核糖核酸酶及其衍生物和/或变体及其应用 | |
| WO2009083968A8 (en) | Novel protein | |
| WO2024182451A3 (en) | Multivalent anti-spike protein binding molecules and uses thereof | |
| TW200745337A (en) | Modified process | |
| FU et al. | Study of microorganism protein and mechanism in solid state fermentation with periodically dynamic changes of air |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/05/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/10/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |